Ads
related to: cirrhosis of the liver stage 4
Search results
Fatty Liver to Cirrhosis Timeline: Prevalence, Treatment, and Outlook
Healthline· 6 days agoIt usually takes years for fatty liver disease to progress to cirrhosis, but several factors affect...
High levels of novel biomarker GDF15 in steatotic liver patients linked to increased liver cancer...
Medical Xpress· 7 hours agoThe findings are published in the journal Alimentary Pharmacology & Therapeutics. Steatotic (fatty) liver disease is on the rise in many countries around the world. A rise in steatotic liver ...
FMT Could Prevent Hepatic Encephalopathy in Cirrhosis
Medscape· 20 hours agoA phase 2 trial of fecal microbiota transplantation to prevent hepatic encephalopathy in cirrhosis...
Childhood sedentariness may cause premature liver damage in young adulthood
Medical Xpress· 5 days agoChildren who are sedentary for more than six waking hours a day have a significantly increased risk...
Viking (VKTX) Falls 10% Despite Upbeat NASH Study Results
Zacks via Yahoo Finance· 1 day agoViking Therapeutics (VKTX) reports promising 52-week treatment data from a mid-stage study on its...
Sequana Medical announces data on alfapump® safety and quality of life to be presented at EASL...
Benzinga· 20 hours agoThe two cohorts were matched for Ascites-Q, age, sex and enrolment MELD-NA, which is a scoring system for assessing the severity of chronic liver disease.
FY2024 EPS Estimates for BioVie Inc. Raised by Cantor Fitzgerald (NASDAQ:BIVI)
ETF DAILY NEWS· 4 days agoBioVie Inc. (NASDAQ:BIVI – Free Report) – Investment analysts at Cantor Fitzgerald lifted their FY2024 earnings per share (EPS) estimates for shares of BioVie in a research report issued to ...
Small Business - Picayune Item | Picayune Item
The Picayune Item· 2 days agoAkero Therapeutics, Inc. (AKRO): A Securities Fraud Class Action Lawsuit Was Filed Against Akero Therapeutics, Inc. PR Newswire RADNOR, Pa., June 4, 2024 RADNOR, Pa., June ...
Small Business - Salisbury Post | Salisbury Post
The Salisbury Post· 2 days agoAt the end of treatment, 33.3% of patients receiving imdusiran for 48 weeks, interferon (IFN) for 24 weeks and ongoing nucleoside analogue (NA) therapy achieved undetectable levels of HBsAg that were maintained in 100% of these patients 24 weeks
